Onclive company information, Employees & Contact Information

Neladalkib Showcases Early Activity in ALK+ Solid Tumors OncLive

FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS OncLive

PRO Data Further Support SERENA-6 Regimen in HR+ Breast Cancer After Emergence of ESR1 Mutations OncLive

Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer OncLive

Subcutaneous Pembrolizumab Shows Possibility of Providing Effective and Convenient Treatment in Oncology OncLive

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma OncLive

RCC Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 OncLive

MPN Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 OncLive

Lung Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 OncLive

Experts Highlight Key Topics to Watch at the 22nd International Myeloma Society Annual Meeting OncLive

CELMoDs Could Augment T-Cell Redirection Therapies for Prolonged Remission in R/R Myeloma OncLive

FDA Approves Linvoseltamab for Relapsed/Refractory Multiple Myeloma OncLive

Imlunestrant Plus Abemaciclib Provides Consistent Benefit Across Key Subgroups of ER+ Advanced Breast Cancer OncLive

Novel ADC Sigvotatug Vedotin Generates Early Efficacy in NSCLC OncLive

FDA Approves Penpulimab for Non-Keratinizing Nasopharyngeal Carcinoma OncLive

FDA Grants Fast Track Status to ZEN-3694 Plus Abemaciclib for Unresectable or Metastatic NUT Carcinoma OncLive

FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma OncLive

Dr Garcia on the Safety of Earlier Use of Lu 177 Vipivotide Tetraxetan PSMA+ mCRPC OncLive

Pasritamig Displays Safety, Durable Disease Control in Heavily Pretreated mCRPC OncLive

FDA Approves Nivolumab Plus Ipilimumab for dMMR/MSI-H Metastatic CRC OncLive

Ventana TROP2 (EPR20043) RxDx Device Receives FDA Breakthrough Device Designation for Dato-DXd Selection in NSCLC OncLive

FDA Approves Retifanlimab for Advanced Anal Cancer OncLive

Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer OncLive

Infinatamab Deruxtecan Shows Encouraging CNS Activity in Extensive-Stage Small Cell Lung Cancer OncLive

Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC OncLive

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer OncLive

AMXT 1501 Plus Difluoromethylornithine Nets FDA Orphan Drug Designation in Neuroblastoma OncLive

Zongertinib Yields Clinical Benefit in Previously Treated, HER2-Mutated, Advanced NSCLC OncLive

Roswell Park-Led Research Reveals a Hidden Vulnerability of Lung Cancer OncLive

Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC OncLive

FDA Green Lights Companion Diagnostic for Telisotuzumab Vedotin in NSCLC OncLive

Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer OncLive

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Based Insights OncLive

Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting OncLive

Perioperative Durvalumab Plus Chemo Meets EFS End Point in Resectable Gastric/GEJ Cancer OncLive

First-Line Maintenance Lurbinectedin Plus Atezolizumab Boosts Survival in ES-SCLC OncLive

Health Canada Authorizes Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC OncLive

FDA Grants Fast Track Designation to CHM CDH17 for Gastroenteropancreatic NETs OncLive

FDA Expands Indication for Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC OncLive

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know OncLive

European Commission Green-Lights Vimseltinib for Symptomatic, Unresectable TGCT OncLive

New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment OncLive

FDA Grants Fast Track Status to EBC-129 for Pancreatic Ductal Adenocarcinoma OncLive

First-Line Ivonescimab Plus Chemo Improves PFS in Advanced Squamous NSCLC OncLive

Myeloma Experts Summarize Key Themes From the 22nd Annual IMS Meeting and Exposition OncLive

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer OncLive

Daraxonrasib Demonstrates Efficacy, Potential to Inhibit Major RAS(ON) Variants in RAS+ PDAC OncLive

FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer OncLive

Zidesamtinib Data Align With Clinical Expectations in Pretreated ROS1+ Advanced NSCLC OncLive

LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC OncLive

Pembrolizumab Plus Olaparib Improves PFS in BRCA Wild-Type Ovarian Cancer OncLive

Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications OncLive

Savolitinib Plus Osimertinib Elicits Durable Responses in Pretreated EGFR-Mutated, MET+ Advanced NSCLC OncLive

T-DXd Plus Pertuzumab Could Add to Antibody-Drug Conjugate Arsenal in HER2+ Breast Cancer OncLive

CBM588 Plus Cabozantinib/Nivolumab Shows Early Activity in Metastatic Renal Cell Carcinoma OncLive

Health Canada Approves Amivantamab/Lazertinib Combo for EGFR+ Advanced NSCLC OncLive

SON-1010 Plus Atezolizumab Is Safe, Displays Preliminary Efficacy in Platinum-Resistant Ovarian Cancer OncLive

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer OncLive

OncLive Polls Reveal Picks for Top Gastrointestinal Cancer Abstracts at ASCO 2025 OncLive

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer With Low/Medium FRα Expression OncLive

FDA Accepts BLA Resubmission for Linvoseltamab in R/R Multiple Myeloma OncLive

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer OncLive

Zongertinib Displays Early Activity and Tolerability in HER2-Mutated Solid Tumors OncLive

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer OncLive

Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer OncLive

Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer OncLive

FDA Approves PSMA PET Imaging Agent TLX007-CDx for Prostate Cancer OncLive

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer OncLive

Lifileucel Sustains Long-Term Responses and Survival in Advanced Melanoma OncLive

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer OncLive

Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer OncLive

Azenosertib Monotherapy Appears Safe and Effective in Ovarian Cancer OncLive

FDA Approves TAR-200 in BCG-Unresponsive NMIBC With CIS OncLive

Capecitabine/Bevacizumab Yields Antitumor Activity and a Favorable Safety Profile in Older mCRC Population OncLive

Dr Graham on Advancements in the Management of Ovarian Cancer OncLive

Abemaciclib/Fulvestrant Improves PFS Across HR+/HER2– Advanced Breast Cancer Subgroups OncLive

PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer OncLive

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma OncLive

Dr Pimenta on Ongoing Therapeutic Challenges in Soft Tissue Sarcomas OncLive

Dr Graham on Notable Ongoing Studies in Ovarian Cancer OncLive

CD19 t-haNK Leads to Complete Responses in Waldenstrom Macroglobulinemia OncLive

Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer OncLive

Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases OncLive

Giants of Cancer Care® Announces the 13th Annual Class of Inductees OncLive

The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC OncLive

Dr Alawadhi on the Link Between Obesity/Overweight and Breast Cancer Outcomes OncLive

FDA Grants Accelerated Approval to Dato-DXd for EGFR+ NSCLC OncLive

EU Grants Conditional Approval of Mirdametinib for NF1-Associated Plexiform Neurofibromas OncLive

FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab Plus Chemo for U.S. Patients With R/R DLBCL OncLive

Dr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer OncLive

FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma OncLive

Anito-Cel Drives Durable Responses in R/R Multiple Myeloma OncLive

Targeted CAR T-Cell Therapies Show Early Efficacy in Solid Tumors With Focus on Mitigating Toxicity OncLive

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL OncLive

Adagrasib Combo Continues to Show Efficacy in KRAS G12C–Mutated NSCLC and PD-L1 ≥50% OncLive

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care OncLive

Tigilanol Tiglate Shows Early Efficacy in Soft Tissue Sarcomas OncLive

Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC OncLive

Dr Matasar on the Use of Odronextamab Monotherapy in R/R DLBCL Following CAR T-Cell Therapy OncLive

Redefining Translational Research and China’s Impact on US Drug Development OncLive